GlassScriptPhysician profile
Kenneth D Candido
NPI 1518937937
$15,206.64
in general payments reported to CMS, 2019-2025
33 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,800 · 2020: $635 · 2021: $5,467 · 2022: $1,522 · 2023: $507 · 2024: $4,513 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,488 · Food and Beverage: $2,243 · Travel and Lodging: $52.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,487.50 |
| Food and Beverage | $2,242.78 |
| Travel and Lodging | $52.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,154.11 | 2019-2025 | Eterna, Proclaim |
| Ferring Pharmaceuticals INC. | $3,673.65 | 2021-2024 | |
| Lilly USA, LLC | $3,600.00 | 2021 | |
| Boston Scientific Corporation | $644.07 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Biotronik Nro, INC. | $520.19 | 2023-2025 | Prospera, Biotronik |
| Avanos Medical | $471.88 | 2019-2023 | Coolief* Cooled Radiofrequency, Trivisc Sodium Hyaluronate |
| Si-Bone, INC. | $271.46 | 2021-2025 | |
| Curonix LLC | $256.25 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $222.97 | 2019-2023 | Sprint Pns System |
| Horizon Therapeutics Plc | $222.79 | 2019-2021 | |
| Stimwave Technologies Incorporated | $192.86 | 2019-2021 | |
| Medtronic, INC. | $190.31 | 2021-2023 | Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $118.82 | 2022 | |
| Zavation Medical Products, LLC | $94.09 | 2025 | |
| Nevro Corp. | $90.49 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $87.03 | 2019-2024 | Belbuca |
| Medtronic USA, INC. | $65.20 | 2019-2020 | |
| Grt US Holding, INC. | $56.00 | 2022 | |
| Nalu Medical, INC. | $49.39 | 2021 | |
| Mindray Ds USA, INC. | $32.67 | 2022 | |
| Vertiflex, INC. | $29.51 | 2019 | |
| Globus Medical, INC. | $24.87 | 2025 | Senza |
| Merz Pharmaceuticals, LLC | $21.78 | 2024 | Xeomin |
| Sumitomo Pharma America, INC. | $20.79 | 2024 | Gemtesa |
| Valinor Pharma, LLC | $19.70 | 2025 | Movantik |
| Tolmar, INC. | $16.49 | 2025 | Eligard, Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2025 | Relistor |
| Uswm, LLC | $16.36 | 2022 | |
| Lenoss Medical INC | $13.24 | 2025 | Osteopearl |
| Kowa Pharmaceuticals America, INC. | $13.22 | 2023 | Seglentis |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Candido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.